| Market Cap | $72.61M-82.5% |
| Revenue (ttm) | n/a |
| Net Income | -$13.63M |
| EPS | -$0.61 |
| Shares Out | 30.83M |
| PE Ratio | n/a |
| Forward PE | -4.44 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 432,429 |
| Open | $2.08 |
| Previous Close | $2.00 |
| Day's Range | $2.00 - $2.35 |
| 52-Week Range | $1.93 - $18.79 |
| Beta | n/a |
| Analysts | none |
| Price Target | $20.00(+749.26%) |
| Earnings Date | Jan 22, 2027 |
About CNXU
Conexeu Sciences Inc. develops collagen-based regenerative tissue scaffold products for applications in medical aesthetics and tissue repair. The company provides patented collagen-based scaffold products, including a collagen extracellular matrix (ECM) scaffold platform for use in medical aesthetics, wound care, tissue repair, facial rejuvenation, and large-volume body contouring such as face, breast, and butt volume restoration. Its CXU collagen gel is an investigational product targeting therapeutic and aesthetic indications, supporting tissue regeneration and aiming to minimize inflammation or fibrosis. The company's solutions are supported by preclinical and peer-reviewed data and are positioned as alternatives to conventional fillers or implants, with products currently investigational and pending regulatory clearance for certain applications. The company serves clients in the beauty, aesthetics, regenerative medicine, and medical sectors, including clinicians and professionals involved in facial rejuvenation, body contouring, wound care, and tissue repair. The company was founded in 2022 and is based in Reno, Nevada.
Conexeu Sciences Inc. Stock Analysis — InsiderScore
Conexeu Sciences Inc. scored higher than 41% of companies evaluated by InsiderBuying, and ranked 48th out of 103 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Conexeu Sciences Inc. bought $500.0K of stock across 1 purchase in the last 90 days, the largest of them $500.0K.
The average purchase added about 6% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
Every buyer already held stock, so each purchase is an increase rather than a first position.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
When insiders bought and sold
1 year · open-market trades onlyNext catalysts
- Jan 22, 2027Earnings report
$CNXU stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in CNXU holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by CNXU's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
CNXU Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New CNXU patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to CNXU from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from CNXU’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Insider Score Trend Over Time
-14.6 since Oct 20Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
